A Phase 2a clinical trial testing RCT2100, Recode Therapeutics’ investigational inhaled mRNA therapy for cystic fibrosis (CF), is fully…
Articles by Patricia Inácio, PhD
The Cystic Fibrosis Foundation is funding a new research project that aims to develop a cell-based strategy…
One year of treatment with Kaftrio lowered levels of certain immune cells implicated in inflammation, led to fewer pulmonary…
People with cystic fibrosis (CF) in Canada are a step closer to gaining public access to Alyftrek, a…
Blackstone Life Sciences is investing $250 million in Anagram Therapeutics to advance ANG003, an oral enzyme replacement therapy…
Children with cystic fibrosis who carry two Trikafta-responsive mutations are significantly more likely to reach normal or near-normal…
In people with cystic fibrosis (CF), the timing of organ transplant — lung, liver, or…
Bioversys has entered into an exclusive collaboration and license agreement with Hackensack Meridian Health (HMH) and its…
The lungs of infants and children with cystic fibrosis (CF) show an early, overactive immune response driven by neutrophils…
Researchers at UCLA have developed a nonviral gene-editing strategy that could help pave the way for one-time treatments for people…